Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02225223 · ClinicalTrials.gov registry record · NA
Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)
A NA study, sponsored by Merit Medical Systems.
- Terminated
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT02225223 is a NA study that was terminated before completion, run by Merit Medical Systems. The registered enrollment target is 35 participants.
The verdict
NCT02225223, a NA study, was terminated before completion, sponsored by Merit Medical Systems.
- TERMINATED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate treating painful metastatic lesions in vertebral bodies with pathologic fractures with targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following radiation therapy.
Interventions
- DEVICE STAR™ Tumor Ablation System
- DEVICE StabiliT® Vertebral Augmentation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02225223
The ClinicalTrials.gov registry entry for NCT02225223 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merit Medical Systems, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which STAR™ Tumor Ablation System is the first listed.
NCT02225223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02225223 about?
NCT02225223 is a clinical study titled "Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)". The purpose of this study is to evaluate treating painful metastatic lesions in vertebral bodies with pathologic fractures with targeted radiofrequency ablation (t-RFA) and vertebral augmentation (VA) prior to or following radiation therapy.
What is the current status of trial NCT02225223?
This trial is currently terminated. It is a NA study. The enrollment target is 35 participants. The study started on 2014-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02225223?
The interventions under investigation include: STAR™ Tumor Ablation System (DEVICE), StabiliT® Vertebral Augmentation System (DEVICE).
Who is sponsoring clinical trial NCT02225223?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.